Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
Drug Classes and Categories01:25

Drug Classes and Categories

2.7K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
2.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

457
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
457

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An alternative method to validate surrogate endpoints in oncology.

BMC medical research methodology·2026
Same author

[Effects of electroacupuncture on the SIRT3/NF-κB /MAPK signaling pathway in the substantia nigra of mice with Parkinson's disease].

Zhen ci yan jiu = Acupuncture research·2026
Same author

Yishen Qianggu Mixture formulation suppresses osteometabolic inflammation by modulating the IL-17/NF-κB/MAPK signaling axis.

Journal of ethnopharmacology·2025
Same author

Exploring the potential mechanisms of acetyl tributyl citrate exposure on osteoarthritis based on novel network toxicology.

Scientific reports·2025
Same author

Regulatory efforts to address the access gap for foreign new drugs in China: the priority review program and related policies.

Global health research and policy·2025
Same author

Association of cortical morphology, white matter hyperintensity, and glymphatic function in frontotemporal dementia variants.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2024

Related Experiment Video

Updated: Jan 6, 2026

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
05:59

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

2.1K

Innovative Drugs Approved in China After Registration Classification Reform: Current Status, Disparities, and

Xingyue Zhu1,2, Die Xiao1

  • 1School of Medicine and Health Management, Guizhou Medical University, Guiyang, Guizhou, China.

Clinical Pharmacology and Therapeutics
|October 11, 2025
PubMed
Summary

China

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method
09:16

Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method

Published on: May 12, 2023

1.5K

Related Experiment Videos

Last Updated: Jan 6, 2026

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
05:59

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

2.1K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method
09:16

Author Spotlight: Optimization of Processing Technology for Tiebangchui with Zanba Based on CRITIC Combined with Box-Behnken Response Surface Method

Published on: May 12, 2023

1.5K

Area of Science:

  • Pharmaceutical Science
  • Drug Regulation
  • Clinical Research

Background:

  • China's National Medical Products Administration (NMPA) reformed drug registration rules in 2016, defining innovative drugs as those new to domestic and global markets.
  • This reform aimed to foster domestic pharmaceutical innovation and align with international standards.

Purpose of the Study:

  • To systematically evaluate the characteristics of innovative drugs approved in China post-reform.
  • To analyze trends in drug types, therapeutic areas, and regulatory pathways for innovative medicines.

Main Methods:

  • A cross-sectional study analyzing innovative small molecules, biologics, and Chinese medicines approved by the NMPA before 2024.
  • Data extracted from NMPA's open databases, including drug information and pivotal trial characteristics.
  • Inclusion criteria specified different application submission timelines for small molecules versus biologics and Chinese medicines.

Main Results:

  • 167 innovative drugs were approved: 58.1% small molecules, 31.1% biologics, 10.8% Chinese medicines.
  • Domestic drugs constituted 86.8%, showing growth from 2018-2024.
  • Oncology was the dominant area (43.7%), especially for biologics (55.8%). Most oncology drugs (90.4%) used surrogate endpoints.
  • Expedited programs accelerated development, but review times often exceeded targets. Chinese medicines faced less regulatory flexibility.

Conclusions:

  • China's pharmaceutical innovation is growing, with domestic small molecules and biologics leading.
  • Oncology remains a key focus, often utilizing surrogate endpoints for faster approval.
  • Further investment in differentiated therapies, financial incentives, and improved regulatory capacity is crucial for global competitiveness.